Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NVG 291

Next Previous
Drug Profile

NVG 291

Alternative Names: NVG-291; NVG-291-R

Latest Information Update: 16 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NervGen Pharma
  • Class Antidementias; Neuroprotectants; Peptides; Vascular disorder therapies
  • Mechanism of Action Receptor-like protein tyrosine phosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Spinal cord injuries
  • Preclinical Hearing loss; Stroke; Traumatic brain injuries
  • Discontinued Alzheimer's disease; Amyotrophic lateral sclerosis; Multiple sclerosis

Most Recent Events

  • 07 Apr 2026 NervGen Pharma plans a 12-week open label extension trial for Spinal cord injuries in USA and Canada (SC),
  • 07 Apr 2026 NervGen Pharma plans to initiate the registrational phase-III RESTORE trial in Spinal cord injuries in the US and Canada in mid-2026 (SC, Injections)
  • 31 Mar 2026 NervGen Pharma completes End-of-Phase II meeting with the US FDA, securing alignment on the registrational phase-III RESTORE study of NVG-291 for Spinal cord injuries

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top